--- title: "Anaptysbio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286153391.md" datetime: "2026-05-12T20:31:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286153391.md) - [en](https://longbridge.com/en/news/286153391.md) - [zh-HK](https://longbridge.com/zh-HK/news/286153391.md) --- # Anaptysbio | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 25.56 M Revenue: As of FY2026 Q1, the actual value is USD 25.56 M, beating the estimate of USD 18.87 M. EPS: As of FY2026 Q1, the actual value is USD -1.84, missing the estimate of USD -0.7988. EBIT: As of FY2026 Q1, the actual value is USD -16.43 M. AnaptysBio, Inc. operates in two segments: Biopharma and Royalty Management. The Biopharma segment focuses on developing immunology therapeutics, while the Royalty Management segment manages financial collaborations for Jemperli with GSK and imsidolimab with Vanda to protect and return royalty value to stockholders. #### Collaboration Revenue Total collaboration revenue for the three months ended March 31, 2026, was $25,556 thousand, entirely from the Royalty Management segment, a decrease from $27,771 thousand for the same period in 2025. #### Operating Expenses Total operating expenses increased to $60,193 thousand for the three months ended March 31, 2026, from $55,310 thousand in the prior year. ##### Research and Development (R&D) Expenses Total R&D expenses decreased to $33,991 thousand for the three months ended March 31, 2026, from $41,180 thousand in the prior year. **Biopharma Segment R&D:** External R&D for ANB033 increased to $9,299 thousand in 2026 from $3,803 thousand in 2025, while Rosnilimab External R&D decreased to $4,594 thousand from $15,026 thousand. ANB101 External R&D remained stable at $1,484 thousand compared to $1,481 thousand, and ANB032 External R&D was -$31 thousand in 2026, down from $3,536 thousand. Preclinical and other unallocated costs decreased to $3,296 thousand from $3,932 thousand, and Internal R&D costs increased to $15,313 thousand from $13,687 thousand. **Royalty Management Segment R&D:** Imsidolimab External R&D was $21 thousand in 2026 compared to -$189 thousand in 2025, and Internal R&D costs were $15 thousand in 2026 compared to -$96 thousand in 2025. ##### General and Administrative (G&A) Expenses Total G&A expenses increased to $26,202 thousand for the three months ended March 31, 2026, from $14,130 thousand in the prior year. **Biopharma Segment G&A:** External G&A increased to $8,721 thousand from $3,848 thousand, and Internal G&A increased to $10,135 thousand from $5,967 thousand. **Royalty Management Segment G&A:** External G&A increased to $3,398 thousand from $1,692 thousand, and Internal G&A increased to $3,948 thousand from $2,623 thousand. #### Loss from Operations Total loss from operations increased to -$34,637 thousand for the three months ended March 31, 2026, compared to -$27,539 thousand for the same period in 2025. The Biopharma segment reported a loss of -$52,811 thousand in 2026, while the Royalty Management segment reported income of $18,174 thousand. #### Other Income (Expense), Net Total other expense, net, increased to -$18,207 thousand in 2026 from -$11,746 thousand in 2025. Interest income decreased to $2,653 thousand in 2026 from $4,413 thousand in 2025, and non-cash interest expense for sale of future royalties increased to -$20,859 thousand in 2026 from -$18,061 thousand in 2025, primarily due to increased GSK Jemperli sales accelerating the expected repayment timing. #### Net Loss AnaptysBio, Inc. reported a net loss of -$52,884 thousand for the three months ended March 31, 2026, an increase from -$39,329 thousand for the same period in 2025. #### Cash Flow from Operating Activities Net cash used in operating activities increased to -$25,919 thousand for the three months ended March 31, 2026, from -$10,700 thousand for the same period in 2025. #### Cash Flow from Investing Activities Net cash provided by investing activities was $34,983 thousand for the three months ended March 31, 2026, compared to $14,847 thousand for the same period in 2025. #### Cash Flow from Financing Activities Net cash provided by financing activities was $1,209 thousand for the three months ended March 31, 2026, a significant change from net cash used in financing activities of -$28,590 thousand in 2025. This was primarily due to $14,021 thousand from common stock issuance, offset by -$12,812 thousand in principal repayments for future royalties. #### Liquidity and Capital Resources As of March 31, 2026, AnaptysBio, Inc. had $286,500 thousand in cash, cash equivalents, and investments. The company believes these resources will fund its operating plan for at least the next twelve months from the issuance of its consolidated financial statements. #### Future Outlook and Strategy AnaptysBio, Inc. completed the separation of its business into two independent, publicly traded companies on April 20, 2026. Following the spin-off, AnaptysBio, Inc. will focus on managing its financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return the value of royalties to its stockholders. The spun-out company, First Tracks Biotherapeutics, Inc., will concentrate on the development and commercialization of innovative therapeutics for autoimmune and inflammatory diseases. ### Related Stocks - [ANAB.US](https://longbridge.com/en/quote/ANAB.US.md) ## Related News & Research - [AnaptysBio menggelar rapat tahunan pemegang saham](https://longbridge.com/en/news/295574498.md) - [Can Gold Make a New High in 2026?](https://longbridge.com/en/news/295569739.md) - [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/295257462.md) - [General Dynamics announces Q3 2026 distribution of R$ 5.39 per unit, payable Nov. 25](https://longbridge.com/en/news/295132633.md) - [ESS Tech reschedules Q2 2026 results conference call to Tuesday evening](https://longbridge.com/en/news/295407778.md)